- Home
- PEBK vs UNCY Comparison
PEBK vs UNCY Comparison
Compare PEBK & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PEBK | UNCY |
|---|---|---|
| Founded | 1912 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.0M | 141.8M |
| IPO Year | 2012 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PEBK | UNCY |
|---|---|---|
| Price | $37.26 | $6.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $44.50 |
| AVG Volume (30 Days) | 17.6K | ★ 480.1K |
| Earning Date | 04-27-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.57% | N/A |
| EPS Growth | 7.58 | ★ 56.25 |
| EPS | ★ 2.41 | N/A |
| Revenue | N/A | ★ $675,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.66 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.96 | $0.45 |
| 52 Week High | $40.74 | $7.57 |
Technical Indicators
Market Signals| Indicator | PEBK | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 43.55 | 49.86 |
| Support Level | $35.24 | $5.90 |
| Resistance Level | $38.03 | $6.82 |
| Average True Range (ATR) | 0.98 | 0.36 |
| MACD | -0.27 | 0.01 |
| Stochastic Oscillator | 19.57 | 41.59 |
Price Performance
Historical ComparisonAbout PEBK Peoples Bancorp of North Carolina Inc.
Peoples Bancorp of North Carolina Inc is a bank holding company. It is a state-chartered commercial bank serving Lincolnton, Newton, Denver, Catawba, Conover, Maiden, Claremont, Hiddenite, Hickory, Charlotte, Cornelius, Raleigh and Cary, North Carolina. It has a diversified loan portfolio with no foreign loans and few agricultural loans. The company's main source of income is dividends declared and paid by the Bank on its capital stock.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.